Objective-In vivo assessment of pathological endothelium within arteriovenous fistula (AVF) could provide new insights into inflow stenosis, a common cause of AVF primary failure in end-stage renal disease patients. Here we developed nanoparticle-based imaging strategies to assess pathological endothelium in vivo and elucidate its relationship to neointimal hyperplasia formation in AVF. Approach and Results-Jugular-carotid AVFs were created in C57BL/6 mice (n=38). Pathological endothelium in the AVF was visualized and quantified in vivo using dextranated magnetofluorescent nanoparticles (CLIO-VT680 [crosslinked iron oxide-VivoTag680]). At day 14, CLIO-VT680 was deposited in AVF, but only minimally in sham-operated arteries. Transmission electron microscopy revealed that CLIO-VT680 resided within endothelial cells and in the intimal extracellular space. Endothelial cells of AVF, but not control arteries, expressed vascular cell adhesion molecule-1 and showed augmented endothelial permeability near the anastomosis. Intravital microscopy demonstrated that CLIO-VT680 deposited most intensely near the AVF anastomosis (P<0.0001). The day 14 intravital microscopy CLIO-VT680 signal predicted the subsequent site and magnitude of AVF neointimal hyperplasia at day 42 (r=0.58, P<0.05). CLIO-VT680 deposition in AVF was further visualized by ex vivo MRI. Conclusions-AVF develop a pathological endothelial response that can be assessed in vivo via nanoparticle-enhanced imaging. AVF endothelium is activated and exhibits augmented permeability, offering a targeting mechanism for nanoparticle deposition and retention in pathological endothelium. The in vivo AVF nanoparticle signal identified and predicted subsequent inflow neointimal hyperplasia. This approach could be used to test therapeutic interventions aiming to restore endothelial health and to decrease early AVF failure caused by inflow stenosis. (Arterioscler Thromb Vasc Biol. 2015;35:189-196.
H emodialysis is a life-sustaining treatment for 1.5 million end-stage renal disease patients across the world. 1 Effective hemodialysis treatment requires reliable large caliber vascular access. Dysfunctional dialysis access disrupts scheduled dialysis treatment and associates with higher mortality rates. [2] [3] [4] Thus, preservation of patent dialysis access is essential to the care of hemodialysis patients. Arteriovenous fistulae (AVFs), the preferred access route for hemodialysis, have an unacceptably high failure rate. 5 After surgical creation, ≤30% to 50% of AVFs are unsuitable for hemodialysis as a result of a failure to mature. In contrast to late AVF failures, which are usually caused by thrombosis and venous neointimal hyperplasia (NH), early AVF failures primarily result from juxta-anastomotic inflow stenosis. 6 Pathologically altered endothelium is implicated in AVF failure. [7] [8] [9] At present, however, there is minimal understanding of the role of pathological endothelium in AVF failure in vivo. The ability to assess AVF endothelium in vivo could furnish new insights into the topography of pathological endothelium and its site-specific relationship to the subsequent development of inflow stenosis, a common cause of AVF failure.
This study tested the hypothesis that fluorescence and MRI imaging of dextran-coated nanoparticle deposition could assess dysfunctional endothelium within AVF. After demonstrating anastomosis-based nanoparticle uptake by AVF, but not shamoperated control vessels, this study explored mechanisms underlying nanoparticle retention in AVF. We further tested the hypothesis that the intensity and location of the pathological endothelial signal on AVF imaging would predict the subsequent extent and location of NH within the maturing AVF. 
Materials and Methods

Results
Measurement of Blood Flow After AVF Creation
Murine AVF were created using an established common carotid artery-jugular vein end-to-side anastomosis approach (Figure IIA in the online-only Data Supplement). [10] [11] [12] [13] The anastomosis was defined as the surgical connection between the carotid artery and the jugular vein. AVFs exhibited a 7-fold increase in carotid arterial blood flow compared with baseline (pre, 0.35±0.03 mL/ min, versus post, 2.56±0.28 mL/min; P<0.0001; Figure IIB in the online-only Data Supplement). Mice that developed acute venous thrombosis immediately after AVF creation were excluded from further study (n=9 of 47, blood flow <0.1 mL/min).
Histological Assessment of Inflow Neointimal Hyperplasia in Murine AVF
To examine whether these experimental AVFs could recapitulate human inflow AVF stenosis, a group of mice were euthanized 42 days after AVF surgery (n=7). Modified Verhoeff Van Gieson histological stain visualized elastin layers within the AVF. NH was evident in the juxta-anastomotic arterial limb. The area of NH, calculated as the area between the lumen and the internal elastic lamina, steadily decreased with increasing distance away from the anastomosis (r=−0.89; P=0.0067; Figure 1 ). Shamoperated contralateral vessels did not develop NH.
CLIO-VT680 Nanoparticles Report on Pathological Endothelium in AVF
To assess the in vivo vascular endothelial response after AVF creation, dextranated magnetofluorescent nanoparticles (CLIO-VT680 [cross-linked iron oxide-VivoTag680], 10 mg Fe/kg) were intravenously injected into day 13 post-AVF surgery mice (n=9). CLIO-VT680 nanoparticles have a hydrodynamic diameter of 49 nm with a 5 nm iron oxide core and can be phagocytosed by murine macrophages, endothelial cells, and smooth muscle cells in vascular disease states. 14, 15 After 24 hours, mice receiving CLIO-VT680 were euthanized and AVF were resected. Fluorescence microscopy revealed that CLIO-VT680 nanoparticles deposited in the juxta-anastomotic arterial segment of the AVF, but minimally in contralateral shamoperated vessels (Figure 2A ). CLIO-VT680 mainly colocalized with CD31-positive endothelial cells. Minor areas of nanoparticle deposition were also evident in the smooth muscle cell-rich superficial medial layer (Figure 2A ). Endothelial cells of AVF, but not sham-operated arteries, expressed vascular cell adhesion molecule-1, a marker of endothelial cell activation ( Figure 2B ). 16 En face confocal analysis of the AVF segment also demonstrated CLIO-VT680 deposition near the anastomosis ( Figure 2C ). Transmission electron microscopy of AVF tissue sections sampled at day 14 revealed the precise localization of the nanoparticles within AVF ( Figure 3A ). The electron dense iron oxide core (5 nm) of the CLIO-VT680 nanoparticles were identified as hypointense signal areas on transmission electron microscopy and localized inside endothelial cells, as well as in the subendothelial intimal space bordered by the internal elastic lamina. Sham-operated control arteries showed minimal nanoparticle deposition.
Nonstandard Abbreviations and Acronyms
As the transmission electron microscopy images revealed subendothelial deposition of CLIO-VT680 nanoparticles in AVFs, we hypothesized that AVF would exhibit abnormal endothelial barrier function. To test this hypothesis, Evans blue was intravenously injected in day 14 animals (n=3), 30 minutes before euthanization to access endothelial permeability. 17 Light microscopy revealed Evans blue deposition in the juxta-anastomostic area of the AVF, indicating increased permeability.
Sham-operated contralateral arteries showed minimal Evans blue staining. Fluorescence reflectance imaging and fluorescence microscopy of Evans blue fluorescence similarly revealed augmented signal in the juxta-anastomotic region of the AVF compared with sham-operated arteries ( Figure 3B ).
In Vivo Assessment of Pathological Endothelium in AVF by Intravital Fluorescence Microscopy
Intravital microscopy (IVM) simultaneously illuminates the molecular and structural details of vascular disease at high resolution in vivo. 18 To determine whether nanoparticle-delineated pathological endothelium in AVF could be imaged in vivo, mice underwent confocal IVM at day 14 (n=9) and day 21 (n=4) post-AVF surgery, 24 hours after CLIO-VT680 administration. AVFs were surgically exposed to allow IVM biological-structural imaging of the anastomosis and the adjacent arterial segment. Areas of pathological endothelium displayed near-infrared fluorescence emission from CLIO-VT680. The vessel wall and lumen were detected and identified jointly by second harmonic generation and fluorescein isothiocyanatedextran signals, respectively ( Figure III in the online-only Data Supplement). 19 IVM coronal Z-stacks were obtained and regions-of-interest were defined as CLIO-VT680-positive areas inside the vessel wall on resliced axial micrographs ( Figure 4A ). The anastomosis was identified by the presence of the AVF sutures. The inability of light to penetrate the nylon sutures precluded analysis of near-infrared fluorescence signals at the site of proximal anastomosis (distance=0 μm).
Analysis of the day 14 IVM data revealed that the highest nanoparticle signal occurred in the juxta-anastomosis arterial segment ( Figure 4A ). In vivo CLIO-VT680 signals decreased linearly as the distance away from the anastomosis increased (r=−0.98; P<0.0001; Figure 4C ). A similar trend was evident in day 21 AVF (r=−0.98; P<0.001; Figure 4C ), with higher CLIO-VT680 target-to-background ratios compared with day 14 AVF, indicating progressive endothelial abnormality in developing AVF. Using the AVF anastomosis as a fiducial marker, matched ex vivo arterial sections similarly demonstrated that day 14 pathological endothelial signal (higher nanoparticle target-tobackground ratio) diminished steadily as the distance from the anastomosis increased (r=−0.96, P<0.0001; Figure 4B and 4D). In vivo and ex vivo nanoparticle target-to-background ratios correlated on matched sections (r=0.59, P<0.0001; Figure 4E ).
Nanoparticle Fluorescence in Pathological Endothelium of AVF Predicts the Development of Arterial Neointimal Hyperplasia Formation
Ex vivo studies link impaired endothelial function to NH and AVF failure. 9, 11 It remains unknown, however, whether imaging of pathological endothelium can quantitatively predict sites of future inflow stenosis. We therefore performed survival IVM imaging of the AVF arterial circuit in day 14 AVF using CLIO-VT680 (n=3), followed by NH assessment at day 42. On day 42, mice were euthanized and the arterial NH was measured using Verhoeff Van Gieson staining. Anastomosis sutures were used as the 0 µm reference point to match day 14 IVM and day 42 histology ( Figure 5A and 5B) . Using the AVF anastomosis as a fiducial marker, we found that both the day 14 in vivo CLIO-VT680 signal and day 42 NH area steadily decreased with the distance from the anastomosis (n=3 mice, r=−0.98, P=0.0009; r=−0.92, P=0.0089; Figure 5C ). The individual day 14 CLIO-VT680 target-to-background ratio values (reflecting the degree of pathological endothelium) predicted the site and magnitude of NH on day 42 (r=0.58, P=0.016; Figure 5D ). A similar correlation was found in an additional group of mice (n=2) using a different batch of CLIO-VT680 (r=0.67, P=0.01, data not shown). The pattern of day 42 NH distribution was similar to the day 14 CLIO signal distribution ( Figure IV in the online-only Data Supplement).
MRI of Pathological Endothelium in AVF
To determine whether a clinical imaging modality could assess pathological endothelial function in AVF, ex vivo MRI was performed on resected day 14 AVF (n=5). Day 14 mice received CLIO-VT680 nanoparticles or PBS before euthanization and tissue resection. CLIO-VT680 nanoparticles are derived from ultrasmall superparamagnetic iron oxide nanoparticles that can induce signal loss in T2-weighted magnetic resonance images. 14 In mice that received the magnetofluorescent CLIO-VT680 nanoparticles, strong near-infrared fluorescence signal emanated from the juxta-anastomotic region (arrow head, Figure 6A ), consistent with the in vivo IVM results. Minimal near-infrared fluorescence signal enhancement occurred in PBS-injected mice. T 2 -weighted rapid acquisition with refocused echoes images demonstrated signal hypointensity around the AVF anastomosis in CLIO-VT680-injected mice, consistent with the IVM and FRI data. Iron oxide deposition in the arterial AVF segment generated lower MRI signal on T2-weighted images compared with the PBS group (signal-to-noise ratio, 41.5±1.8 CLIO versus 64.9±1.8 PBS; P=0.003; Figure 6B ).
Discussion
This study reports the development of a novel nanoparticle-based imaging approach to map and quantify murine AVF-induced pathological endothelial function in vivo. It showed that in the early stage, the in vivo AVF endothelial injury response predicted the development of later stage AVF arterial NH and inflow stenosis. The greatest degree of endothelial injury and NH occurred in the juxta-anastomotic arterial segment of the AVF.
Endothelial cells near the AVF anastomosis exhibited greater retention of CLIO nanoparticles and showed increased permeability and vascular cell adhesion molecule-1 expression. After AVF creation in humans, arterial blood flow usually increases 40-fold to 1000 mL/min. 20 The response to augmented blood flow as well to the initial surgical procedure can induce endothelial dysfunction, characterized by an imbalance between endothelium-derived vasodilators and vasoconstrictors, abnormal leukocyte-endothelial interactions, and an increased expression of adhesion molecules, as well as impaired vascular integrity and increased permeability. 21, 22 Indeed, we found heightened vascular cell adhesion molecule-1 expression and Evans blue-delineated endothelial permeability near the AVF anastomosis ( Figure 3B ), the area that ultimately developed the greatest degree of NH and stenosis. Augmented endothelial cell activation and endothelial permeability in AVF further provide mechanisms for the deposition of CLIO-VT680 nanoparticles in endothelial cells and the subendothelial space, respectively, as revealed by transmission electron microscopy ( Figure 3A) . Although smooth muscle cells (SMCs) within atheroma may phagocytose CLIO nanoparticles, 14 we found little nanoparticle deposition in SMCs within AVF. This observation might relate to differential phagocytic profiles of SMCs in differing arterial disease states, 23 as well as reduced access of CLIO nanoparticles to the deeper medial layers.
Although many studies have elucidated mechanisms underlying late AVF failure, such as venous NH and thrombosis, only a few studies have studied in vivo mechanisms underlying primary AVF failure, a major clinical problem. The primary failure rate of AVF reaches 30% to 50%. 24, 25 Inflow stenosis as a subset of juxta-anastomotic stenosis accounts up to one-third of AVF cases referred to interventional centers. [26] [27] [28] At present, scant data shed light on in vivo biological mechanisms underlying inflow stenosis. This study provides new knowledge into the relationship between in vivo regional AVF-related endothelial injury and subsequent inflow neointimal formation. We found that the degree and location of pathological endothelium could predict the development of NH at a later stage. The validated experimental methodology here provides a new approach to investigate genetic or pharmacological manipulations of endothelial function in vivo and to assess its subsequent effects on the development of NH and inflow stenosis in AVF. In addition, future studies can also investigate the possible contributions of comorbidities relevant to renal patients, such as hyperlipidemia, diabetes mellitus, and hypertension to mechanisms of AVF failure.
The most commonly used clinical imaging method to assess AVF patency is duplex ultrasound. 29 Multidetector computed tomography is another noninvasive tool that can evaluate the entire AVF circuit. 30 X-ray angiography provides structural information and guides AVF treatment, but is invasive. Additional limitations of CT and invasive angiography include the inability to image the biological processes underlying AVF failure, as well as radiation exposure and the risk of contrastinduced nephropathy. Furthermore, none of the current AVF imaging methods accurately predicts inflow stenosis, nor leads to improved AVF patency rates. [31] [32] [33] In this study, the initial results with MRI of iron oxide nanoparticle deposition illustrate a possible path to image pathological endothelium in AVF in humans. Clinical magnetic nanoparticles, such as ferumoxytol, are similar to the CLIO-VT680 nanoparticles used here and also induce MRI signal loss on T 2 -weighted images. 34 Although our feasibility study was limited to ex vivo MRI at high-field strength in mice, the larger size and more superficial location of arm AVFs in human subjects might enable noninvasive ferumoxytol-enhanced MRI of pathological endothelial function. New in vivo imaging strategies that can identify AVFs at risk for inflow stenosis offer the opportunity to decrease the early fistula failure rate and improve dialysis patients' outcomes. Such high-risk patients might be candidates for surgical AVF revision, endovascular treatment, or novel proendothelial healing approaches to reduce AVF failure. This study has limitations. Although the used murine AVF approach of carotid artery mobilization differs from the clinical practice of vein mobilization, this murine model is well established experimentally and recapitulates many of the features of human AVF, including inflow stenosis. [10] [11] [12] [13] Venous side juxtaanastomotic stenosis, another common cause of AVF failure, could not be imaged in vivo in this study because of limited light penetration through surgery-induced scar tissue. In this first proof-of-concept study, AVF function was investigated in normal mice without uremia. Evaluation of the AVF endothelial injury response in uremic mice will be of substantial interest in future investigations. Confocal IVM has limited depth sensing of ≤200 μm, restricting in vivo insights into AVF to the top arc of murine AVF. In contrast, ex vivo fluorescence microscopy can image the full depth of the fluorescence signals in the vessel, which may explain a moderate rather than strong correlation between in vivo and ex vivo CLIO-VT680 signal intensities. Multiphoton IVM approaches may allow deeper high-resolution imaging and could help address this issue and also allow venous circuit imaging. Although this study did not probe directly possible mechanisms of modified endothelial function, altered endothelial shear stress influenced by AVF geometry could contribute to the development of dysfunctional endothelium after AVF creation. 35, 36 In conclusion, pathological endothelium in murine AVF can be assayed in vivo by fluorescence and MRI of dextranated nanoparticle deposition. The extent and location of abnormal AVF endothelium predicted the local degree of NH formation. Such imaging approaches offer the ability to predict the likelihood and even the specific location of inflow stenosis and further provide a theranostic framework to assess therapies aiming to restore endothelial health and reduce primary AVF failure. Figure 6 . Ex vivo molecular MRI of pathological endothelial signals using the CLIO-VT680 magnetofluorescent nanoparticle reporter. Day 14 AVF underwent ex vivo MRI 24 h after injection of CLIO-VT680 (n=3) or control PBS (n=2). A, Fluorescence reflectance imaging (FRI) demonstrated strong focal NIRF signal enhancement (arrowhead) at the anastomosis in CLIO-VT680injected animals (top row). In contrast, minimal fluorescence signal was noted in PBS-injected AVF tissues (right column). T2*-weighted rapid acquisition with relaxation enhancement (RARE) images by 7T MRI of the same, respective AVF showed strong signal loss (arrowhead) in the arterial segment of CLIO-VT680 injected animals. In PBS-injected mice, MRI signal loss was more focal and restricted to the suture zone of the anastomosis. Scale bar, 1 mm. FRI and MRI images, respectively, processed and windowed identically. B, Signal-to-noise ratio analysis of the arterial segment adjacent to the anastomosis showed reduced signal-to-noise ratio in the CLIO-VT680 group compared with the PBS group (P=0.003, unpaired t test).
